FindTrial
Sign In

The dose effect optimization of transcutaneous electrical acupoint stimulation in the treatment of different types of acute pain after laparoscopic assisted transvaginal hysterectomy based on the deep learning model

The dose effect optimization of transcutaneous electrical acupoint stimulation in the treatment of different types of acute pain after laparoscopic assisted transvaginal hysterectomy based on the deep learning model

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093634
Enrollment
Unknown
Registered
2024-12-09
Start date
2024-12-09
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Transcutaneous acupoint electrical stimulation group:Transcutaneous acupoint electrical stimulation group

Sponsors

Wenzhou Medical University Affiliated First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologists (ASA) grade I~III; 2. Age 18~75 years old; 3. Elective laparoscopic-assisted transvaginal hysterectomy; 4. Able to communicate, understand and sign informed consent; 5. No cognition, communication disorders, or mental abnormalities; 6. Body mass index 18Kg/m2< BMI=31kg/m2.

Exclusion criteria

Exclusion criteria: 1. There are surgical incisions or surgical scars in the meridians and meridians; 2. Local skin infection in the meridian acupoints; 3. Nerve damage to upper or lower limbs; 4. History of spinal surgery; 5. Participated in other clinical trials in the past four weeks; 6. Unable to understand NRS score and not able to use PCA; 7. Patients with pacemakers; 8. Patients with positive urine pregnancy test; 9. Patients with preoperative pain, using central analgesic drugs, opioid addiction and dependence; 10. Severe central nervous system disease and severe mental illness before surgery; 11. The surgery required an enterostomy; 12. Patients with a history of alcoholism; 13. Patients with endotracheal intubation who need to be transferred to ICU for treatment after surgery; 14. Long-term use of hormone drugs and allergies; 15. Serious complications such as heavy bleeding > 2000ml are expected during the operation; 16. Patients with abnormal liver and kidney function (ALT, AST, BUN, CR exceeding the normal value by 1.5 times); 17. Serum K+>5.5mmol/L or serum K+<3.0mmol/L; 18. Preoperative hemoglobin <7g/dl; 19. Those who are considered unsuitable by the investigator to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Visceral pain;Incision pain;Low back pain;—

Countries

China

Contacts

Public ContactWenwen Du

Wenzhou Medical University Affiliated First Hospital

Dwwwenyi@163.com+86 150 8892 5016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026